Edition:
United Kingdom

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

1.67USD
23 May 2018
Change (% chg)

$-0.00 (-0.30%)
Prev Close
$1.67
Open
$1.68
Day's High
$1.68
Day's Low
$1.67
Volume
839
Avg. Vol
26,221
52-wk High
$6.58
52-wk Low
$0.89

Latest Key Developments (Source: Significant Developments)

Neuralstem Q1 Loss Per Share $0.14
Tuesday, 15 May 2018 

May 15 (Reuters) - Neuralstem Inc ::NEURALSTEM PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FISCAL RESULTS.Q1 LOSS PER SHARE $0.14.CASH AND INVESTMENTS WAS $9.7 MILLION AT MARCH 31, 2018 AS COMPARED TO $11.7 MILLION AT DECEMBER 31, 2017.NEURALSTEM - EXPECTS EXISTING CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS TO FUND OPSS BASED ON CURRENT PLANS, INTO Q1 2019.  Full Article

Neuralstem Q3 loss per share $0.01
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Neuralstem Inc :Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update.Q3 loss per share $0.01.Neuralstem - ‍expect to provide detailed update on corporate strategy after post-phase 2 meeting with fda in h1 2018​.Neuralstem Inc - ‍ recent financing further extended co's cash runway to sufficiently support continued research on NSI-189 and to support operations​.Neuralstem Inc - ‍plans to meet with U.S. Food and Drug Administration in first half of 2018 to discuss clinical development path for NSI-189​.  Full Article

Neuralstem says filed for a non-timely 10-Q - SEC filing
Tuesday, 9 Aug 2016 

Neuralstem Inc : Says it has filed for a non-timely 10-Q - SEC filing . Says unable to file quarterly report on form 10-Q for period ended June 30, 2016 due to difficulty in obtaining required information Source: (http://bit.ly/2b0Z3SN ) Further company coverage: [CUR.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Neuralstem Announces First Surgery Completed In Cervical Cohort Of Phase 1 Clinical Trial In Patients With Chronic Spinal Cord Injury

* NEURALSTEM ANNOUNCES FIRST SURGERY COMPLETED IN CERVICAL COHORT OF PHASE 1 CLINICAL TRIAL IN PATIENTS WITH CHRONIC SPINAL CORD INJURY Source text for Eikon: Further company coverage: